Urothelial papilloma of the bladder: A review of 34 de novo cases

American Journal of Surgical Pathology

Volumn 28, Issue 12, 2004, Pages 1615-1620

  Magi Galluzzi, Cristina ^a,b   Epstein, Jonathan I ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Bladder; Papilloma; Prognosis; Progression; Recurrence

Indexed keywords

ADULT; AGED; BLADDER PAPILLOMA; CANCER INVASION; CANCER MORTALITY; CELL VACUOLE; DYSPLASIA; FEMALE; FOLLOW UP; HUMAN; HYPERPLASIA; INCIDENCE; LAMINA PROPRIA; LYMPH VESSEL; MALE; METAPLASIA; MITOSIS RATE; MORPHOLOGY; RETROSPECTIVE STUDY; REVIEW; SEX RATIO; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME; UROGENITAL TRACT TUMOR; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAPILLOMA; PROGNOSIS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 9444252896     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200412000-00010     Document Type: Review

References (23)

1. Alsheikh, Mohamedali Z, Jones E, et al. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod Pathol. 2001;14:267-272.
2. Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch. 2002;441:109-116.
3. Bostwick DG, Ramnani D, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am. 1999;26:493-507.
4. Campbell PA, Conrad RJ, Campbell CM, et al. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome. Br J Urol Int. 2004;93:1228-1231.
5. Cheng L, Darson M, Cheville JC, et al. Urothelial papilloma of the bladder: clinical and biologic implications. Cancer. 1999;86:2098-2101.
6. Chow NH, Cairns P, Eisenberger CF, et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer. 2000;89:514-518.
7. Cina SJ, Lancaster-Weiss KJ, Lecksell K, et al. Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Pathol Lab Med. 2001;125:646-651.
8. Desai S, Lim SD, Jimenez RE, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000;13:1315-1323.
9. Eble JN, Sauter G, Epstein JI, et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Geneva: World Health Organization, 2004.
10. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder: Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435-1448.
11. Fujii Y, Kawakami S, Koga F, et al. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. Br J Urol Int. 2003;92:559-562.
12. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet. 1999;353:974-977.
13. Holmang S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency, and DNA ploidy. J Urol. 2001;165:1124-1128.
14. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder: can biologic potential be predicted from histologic grading? Cancer. 1987;60:2766-2774.
15. Lerman RI, Hutter RV, Ritter F, et al. The association of benign bladder papilloma with cancers of sites other than the bladder and ureter. J Urol. 1970;104:418-421.
16. Lerman RI, Hutter RV, Whitmore WF Jr. Papilloma of the urinary bladder. Cancer. 1970;25:333-342.
17. McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol. 2003;16:623-629.
18. Mostofi FK, Sesterhenn IA, Davis CJ Jr. Dysplasia Versus Atypia Versus Carcinoma In Situ of Bladder. New York: Churchill Livingstone, 1988.
19. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. Presented at International Classification of Tumor, 19, Geneva, 1973.
20. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology. 2002;60:315-319.
21. Soini Y, Turpeenniemi-Hujanen T, Kamel D, et al. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer. 1993;68:1029-1035.
22. Uchida T, Wada C, Ishida H, et al. p53 mutations and prognosis in bladder tumors. J Urol. 1995;153:1097-1104.
23. Van Rhijn BW, Montironi R, Zwarthoff EC, et al. Frequent FGFR3 mutations in urothelial papilloma. J Pathol. 2002;198:245-251.